ARS Pharmaceuticals (SPRY) news
Recent news
ARS Pharmaceuticals Q2 operating expenses USD 95.123 million
AInvest Wire · Aug 13, 2026ARS Pharmaceuticals Inc: total 2026 cash-based operating expenses, excluding COGS, lowered to $248 mln
AInvest Wire · Jun 24, 2026ARS Pharmaceuticals Inc: reaffirms Nefly base business supports a path to cash-flow breakeven in 2027
AInvest Wire · Jun 24, 2026ARS Pharma sinks 25% after providing financial update
ARS Pharmaceuticals announced commercial and financial updates on June 24, 2026, including a reduction of FY 2026 cash-based operating expenses to approximately $248 million and reaffirmation of its path to achieve cash-flow breakeven in 2027, following which its stock declined by 25%; the updates…
AInvest Wire · Jun 24, 2026ARS: reaffirms path to reach cash-flow breakeven in 2027
ARS Pharmaceuticals, Inc. (Nasdaq: SPRY) reaffirmed its path to achieving cash-flow breakeven by 2027, based on its current financial position and strategic initiatives. As of March 31, 2026, the company held $201.0 million in cash, cash equivalents, and short-term investments, which it believes is…
AInvest Wire · Jun 24, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.